An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma-Reference-Cited by-同舟云学术

An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma

Published:2020-12-16 Issue:42 Volume:27 Page:7159-7167
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Rolla Giovanni¹^ORCID,Heffler Enrico²^ORCID,Pizzimenti Stefano³^ORCID,Michils Alain⁴^ORCID,Malinovschi Andrei⁵^ORCID

Affiliation:

1. Department of Medical Sciences, Allergy and Clinical Immunology AO Mauriziano, University of Torino, Torino, Italy

2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

3. Respiratory Medicine Unit, National Health System, ASL Citta di Torino, Torino, Italy

4. Chest Department, Erasme University Hospital, Universite libre de Bruxelles, Brussels, Belgium

5. Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden

Abstract

Asthma is a heterogeneous disease with regard to the inflammatory pathways activated. In recent years, biologic drugs (monoclonal antibodies) directed towards specific components of type 2 inflammation have been approved for the treatment of severe asthma. Phenotyping of patients with severe asthma and evaluation of biomarkers have been recommended to help identify patients who are candidates for treatment with biologics and to monitor treatment responses. Fractional exhaled Nitric Oxide (FeNO) is a biomarker of type 2 inflammation in asthma, signaling activation of Interleukin (IL)-4/IL-13 pathway. FeNO could be useful to assess treatment response or identify candidates for a specific drug that acts on type 2 inflammation mechanisms linked to Nitric Oxide (NO) production, such as the IL-4/IL-13 pathway or upstream processes. The value of FeNO as a biomarker predictive of responses to the biologics available for treating severe asthma is discussed based on the published studies at the moment of the review.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference56 articles.

1. Global initiative for asthma difficult-to-treat and severe asthma guidelines. Available at: ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html">http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (Accessed Date: 15th October, 2020).

2. Pavord I.D.; Mathieson N.; Scowcroft A.; Pedersini R.; Isherwood G.; Price D.; The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis. NPJ Prim Care Respir Med 2017,27(1),17

3. Chung K.F.; Wenzel S.E.; Brozek J.L.; Bush A.; Castro M.; Sterk P.J.; Adcock I.M.; Bateman E.D.; Bel E.H.; Bleecker E.R.; Boulet L.P.; Brightling C.; Chanez P.; Dahlen S.E.; Djukanovic R.; Frey U.; Gaga M.; Gibson P.; Hamid Q.; Jajour N.N.; Mauad T.; Sorkness R.L.; Teague W.G.; International ERS/ATS guidelines on defini-tion, evaluation and treatment of severe asthma. Eur Respir J 2014,43(2),343-373

4. O’Neill S.; Sweeney J.; Patterson C.C.; Menzies-Gow A.; Niven R.; Mansur A.H.; Bucknall C.; Chaudhuri R.; Thomson N.C.; Brightling C.E.; O’Neill C.; Heaney L.G.; British thoracic society difficult asthma network. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015,70(4),376-378

5. Pavord I.D.; Beasley R.; Agusti A.; Anderson G.P.; Bel E.; Brusselle G.; Cullinan P.; Custovic A.; Ducharme F.M.; Fahy J.V.; Frey U.; Gibson P.; Heaney L.G.; Holt P.G.; Humbert M.; Lloyd C.M.; Marks G.; Martinez F.D.; Sly P.D.; von Mutius E.; Wenzel S.; Zar H.J.; Bush A.; After asthma: redefining airways diseases. Lancet 2018,391(10118),350-400

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps;Frontiers in Immunology;2023-03-30

2. Exhaled nitric oxide in asthma: from diagnosis to management;Current Opinion in Allergy & Clinical Immunology;2022-11-24

3. Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab;Journal of Investigational Allergy and Clinical Immunology;2022-09-01

4. Understanding the Cellular Sources of the Fractional Exhaled Nitric Oxide (FeNO) and Its Role as a Biomarker of Type 2 Inflammation in Asthma;BioMed Research International;2022-05-02

5. Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital;World Allergy Organization Journal;2021-09